不可切除或复发性小肠腺癌全身治疗的单机构分析

A Single Institutional Analysis of Systemic Therapy for Unresectable or Recurrent Small Bowel Adenocarcinoma.

作者信息

Makino Shunichiro, Takahashi Hidekazu, Haraguchi Naotsugu, Nishimura Junichi, Hata Taishi, Matsuda Chu, Ikenaga Masakazu, Murata Kohei, Yamamoto Hirofumi, Doki Yuichiro, Mori Masaki, Mizushima Tsunekazu

机构信息

Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.

Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan

出版信息

Anticancer Res. 2017 Mar;37(3):1495-1500. doi: 10.21873/anticanres.11476.

DOI:10.21873/anticanres.11476

PMID:28314324

Abstract

BACKGROUND

Small bowel adenocarcinoma (SBA) is rare. For unresectable or recurrent SBA, systemic treatment is the only potentially promising option.

PATIENTS AND METHODS

This retrospective study included 13 patients with SBA treated at our Institute. All patients received fluorouracil- or fluoropyrimidine-based regimens. We analyzed associations between the progression-free interval (PFI) and therapeutic regimen (n=17) and patient characteristics.

RESULTS

The 5-year overall survival of patients with SBA was 23.5%. The 5-year relapse-free survival of patients with curatively resected (R0 or R1) SBA (n=6) was 45%. Patients with unresectable or recurrent SBA (n=10) had a median overall survival time of 28.0 months. No factor was significantly associated with PFI, except the number of treatment regimens required: patients that received only one line of treatment survived significantly longer than those receiving multiple lines.

CONCLUSION

Fluorouracil- or fluoropyrimidine-based regimens might effectively treat unresectable or recurrent SBA. We did not investigate any additive agents that might have increased efficacy of these regimens.

摘要

背景

小肠腺癌（SBA）较为罕见。对于无法切除或复发的SBA，全身治疗是唯一可能有前景的选择。

患者与方法

这项回顾性研究纳入了在我院接受治疗的13例SBA患者。所有患者均接受了基于氟尿嘧啶或氟嘧啶的治疗方案。我们分析了无进展生存期（PFI）与治疗方案（n = 17）及患者特征之间的关联。

结果

SBA患者的5年总生存率为23.5%。接受根治性切除（R0或R1）的SBA患者（n = 6）的5年无复发生存率为45%。无法切除或复发的SBA患者（n = 10）的中位总生存时间为28.0个月。除所需治疗方案的数量外，没有因素与PFI显著相关：仅接受一线治疗的患者的生存期明显长于接受多线治疗的患者。